RECORD // Company

Evommune, Inc.

Built 2026-11-21T06:07:54Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Matched by name only, not merged (3)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Evommune, Inc. · Ctgov · same registered legal name as 'Evommune, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • EVOMMUNE, INC. · East licences · same registered legal name as 'Evommune, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • EVOMMUNE, INC. · Ny corps · same registered legal name as 'Evommune, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

3 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-12 · accession 0001193125-26-458385

ItemValuePeriodFormFiledAccessionReport
Revenue$03 months ended 2026-09-3010-Q2026-11-120001193125-26-4583852026-11-21 06:07 UTCReport an error
Net income (loss)$-30,877,0003 months ended 2026-09-3010-Q2026-11-120001193125-26-4583852026-11-21 06:07 UTCReport an error
Cash and cash equivalents$47,570,000at 2026-09-3010-Q2026-11-120001193125-26-4583852026-11-21 06:07 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0002044725
Ticker
EVMN
EIN
850742575
CUSIP
30054Y107
Record ID
sx:sec:0002044725

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

36 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-17SEC EDGAR company profile2026-11-21 06:07 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-17SEC EDGAR company profile2026-11-21 06:07 UTCReport an error
State of incorporationDE2026-11-17SEC EDGAR company profile2026-11-21 06:07 UTCReport an error
Fiscal year end (MMDD)12312026-11-17SEC EDGAR company profile2026-11-21 06:07 UTCReport an error
Business address1891 PAGE MILL RD, PALO ALTO, CA2026-11-17SEC EDGAR company profile2026-11-21 06:07 UTCReport an error
ExchangesNYSE2026-11-17SEC EDGAR company profile2026-11-21 06:07 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$13,000,0002025-12-3110-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax2026-11-21 06:07 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-68,870,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-21 06:07 UTCReport an error
Total assets (at 2025-12-31)$224,946,0002025-12-3110-K, XBRL Assets2026-11-21 06:07 UTCReport an error
Stockholders' equity (at 2025-12-31)$205,566,0002025-12-3110-K, XBRL StockholdersEquity2026-11-21 06:07 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$44,063,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-21 06:07 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-76,441,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-21 06:07 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$235,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-21 06:07 UTCReport an error
Operating lease liabilities (at 2025-12-31)$1,532,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-21 06:07 UTCReport an error
Form D total offering amount (D filed 2025-01-08)$115,499,9562025-01-08D2026-11-21 06:07 UTCReport an error
Form D total amount sold (D filed 2025-01-08)$115,499,9562025-01-08D2026-11-21 06:07 UTCReport an error
Form D industry groupOther2025-01-08D2026-11-21 06:07 UTCReport an error
Form D revenue rangeDecline to Disclose2025-01-08D2026-11-21 06:07 UTCReport an error
Form D date of first sale2024-10-302025-01-08D2026-11-21 06:07 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-12)On November 12, 2026, Evommune, Inc. (the “Company”) issued a press release providing a business update and announcing its financial results for the third quarter ended September 30, 2026 (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1 and is incorporated by reference. The information in this Item 2.02, including Exhibit 99.1 hereto, is being “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Item 2.02…2026-11-12SEC EDGAR 8-K 0001193125-26-458329 (text as filed, excerpt)2026-11-21 06:07 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-11-12)On November 12, 2026, the Company updated its corporate presentation to reflect certain business updates. The presentation is available in the “Investors & Media” section of the Company's website at ir.evommune.com, a copy of which is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein. The Company's website and any information contained on the Company's website are not incorporated by reference into this Current Report on Form 8-K. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.2 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or…2026-11-12SEC EDGAR 8-K 0001193125-26-458329 (text as filed, excerpt)2026-11-21 06:07 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-11-05)On November 5, 2026, the Company issued a press release announcing a live webcast on EVO570. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The Company will make available a copy of the presentation from the webcast on the News & Events page of the Company’s website at https://ir.evommune.com/news-events/ir-calendar. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act. The information in this Item 7.01, including…2026-11-05SEC EDGAR 8-K 0001193125-26-448443 (text as filed, excerpt)2026-11-21 06:07 UTCReport an error
8-K Item 1.01, Entry into a Material Definitive Agreement (filed 2026-11-04)Hinova Pharmaceuticals Inc. License Transaction License Agreement On November 4, 2026, Evommune, Inc. (the “Company”) entered into an Exclusive License Agreement (the “License Agreement”) with Hinova Pharmaceuticals Inc., a company incorporated in the People’s Republic of China (“Hinova”). Pursuant to the License Agreement and subject to certain rights retained by Hinova, Hinova granted the Company the exclusive and sublicensable rights to develop, manufacture, commercialize and otherwise exploit Hinova’s Vav Guanine Nucleotide Exchange Factor 1 (“VAV1”) degraders, including the molecular glue degrader EVO570 (formerly HC118 and known as HB570 in Greater China) (collectively, the…2026-11-04SEC EDGAR 8-K 0001193125-26-447608 (text as filed, excerpt)2026-11-21 06:07 UTCReport an error
8-K Item 3.02, Unregistered Sales of Equity Securities (filed 2026-11-04)The disclosures set forth in Item 1.01 above regarding the Private Placement and the Warrants are incorporated into this Item 3.02. Based in part upon the representations of Hinova in the Licensing Agreement and the Warrants, the offering and sale of the Licensing Securities will be exempt from registration under Rule 903 of Regulation S promulgated under the Securities Act. The Licensing Securities have not been registered under the Securities Act or any state securities laws, and the Licensing Securities may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from the registration requirements. The sale of the Licensing Securities did…2026-11-04SEC EDGAR 8-K 0001193125-26-447608 (text as filed, excerpt)2026-11-21 06:07 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-11-04)On November 4, 2026, the Company issued a press release announcing the License Agreement. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. On November 4, 2026, the Company issued a press release announcing the Private Placement. A copy of the press release is attached hereto as Exhibit 99.2 and incorporated herein by reference. On November 4, 2026, the Company made available a presentation to be used in meetings with investors on the Company’s website. A copy of the presentation is attached hereto as Exhibit 99.3 and incorporated herein by reference. 2 The information furnished under this Item 7.01, including Exhibits 99.1, 99.2 and 99.3…2026-11-04SEC EDGAR 8-K 0001193125-26-447608 (text as filed, excerpt)2026-11-21 06:07 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-11-04)Based upon preliminary estimates and information available to the Company, it estimates that the gross proceeds from the Private Placement before deducting placement agent fees and commissions, together with its cash, cash equivalents, and investments as of September 30, 2026, will be approximately $292.3 million following the closing of the Private Placement, and will be sufficient to fund the Company’s operating expenses and capital expenditure requirements into the second half of 2029. This amount has not been audited, reviewed, or compiled by the Company’s independent registered public accounting firm. The Company’s actual cash, cash equivalents and investments as of September 30, 2026…2026-11-04SEC EDGAR 8-K 0001193125-26-447608 (text as filed, excerpt)2026-11-21 06:07 UTCReport an error
Largest institutional holder #1 (13F as filed): EQT Fund Management S.a r.l.$70,281,6802026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 06:07 UTCReport an error
Largest institutional holder #2 (13F as filed): RA CAPITAL MANAGEMENT, L.P.$46,443,7392026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 06:07 UTCReport an error
Largest institutional holder #3 (13F as filed): Pivotal bioVenture Partners Investment Advisor LLC$25,609,0722026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 06:07 UTCReport an error
Largest institutional holder #4 (13F as filed): JPMORGAN CHASE & CO$23,374,6372026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 06:07 UTCReport an error
Largest institutional holder #5 (13F as filed): RTW INVESTMENTS, LP$19,964,7032026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 06:07 UTCReport an error
Largest institutional holder #6 (13F as filed): Nan Fung Group Holdings Ltd$19,151,3152026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 06:07 UTCReport an error
Largest institutional holder #7 (13F as filed): Point72 Asset Management, L.P.$19,071,8012026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 06:07 UTCReport an error
Largest institutional holder #8 (13F as filed): ANDERA PARTNERS$18,499,5472026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 06:07 UTCReport an error
Largest institutional holder #9 (13F as filed): EVENTIDE ASSET MANAGEMENT, LLC$16,069,3252026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 06:07 UTCReport an error
Largest institutional holder #10 (13F as filed): Vestal Point Capital, LP$13,290,0002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 06:07 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.